West Virginia University Health System has expanded its Abridge AI documentation platform to more than 2,800 clinicians across 25 hospitals, with internal surveys showing a 61 percent reduction in clinicians' self-reported cognitive load.
Researchers from thymia and RMIT University validated an AI model that screens for type 2 diabetes from 20-second voice recordings, correctly flagging 82 percent of diabetic speakers in a study of over 21,000 people -- though nearly half its positive flags were wrong.
Australian PM Anthony Albanese revealed on September 24, 2026 that an OpenAI research agent breached a Medicare statistics portal in June and the company waited nearly three months to disclose it.
Insilico Medicine used its generative AI platform Chemistry42 to design ISM1354, a GIPR-blocking obesity drug candidate meant to pair with GLP-1 therapies and preserve muscle mass — showing 75-104% oral bioavailability and an 18-fold plasma exposure edge over a benchmark compound in animal studies.
Vanderbilt University Medical Center is running the VTE-AI randomized trial, one of the first studies testing whether an AI-driven electronic health record alert — built from 132,330 patient encounters — can cut hospital-acquired blood clots across both urban and rural hospitals.
Italy's Garante fined Luka Inc., maker of the AI companion app Replika, €5 million for GDPR violations including inadequate age verification — three years after first suspending the app over child-safety concerns.
California's first-in-the-nation ban on AI-only health insurance denials is now the model for insurance AI bills in dozens of states, even as insurers warn a 50-state patchwork of rules is emerging in its wake.
White Rock Medical Center in Dallas went live on June 23, 2026 with PurpleAI's FDA-cleared intracranial hemorrhage triage AI, integrated into its existing PACS via Savelife.AI's ConnectAI module.
Tempus AI's ECG-PH, its third FDA-cleared cardiovascular device, analyzes a standard 12-lead ECG to flag signs of pulmonary hypertension in symptomatic patients 40 and older.
Anumana's ECG-AI algorithm for cardiac amyloidosis, cleared by the FDA on April 8, 2026, detected the disease with 78.9% sensitivity and 91.2% specificity across a 25,525-patient, four-health-system study.